BibTex RIS Kaynak Göster

Matrix metalloproteinases and lung cancer

Yıl 2006, Cilt: 21 Sayı: 2, 53 - 56, 01.03.2006

Hilal Oğuz Soydinç Hakan Çamlıca Derya Duranyıldız Esra Kaytan Sağlam Faruk Taş Vildan Yasasever Nejat Dalay

Öz

OBJECTIVES The aim of this study was to determine the pretreatment levels of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase 1 (TIMP-1) in lung cancer patients. METHODS We investigated the serum MMP-9 and TIMP-1 values in 20 lung cancer patients by ELISA and the results were compared with the controls (n=20). RESULTS MMP-9 (p

Anahtar Kelimeler

Lung Neoplasms Matrix Metalloproteinase 9 Tissue Inhibitor of Metalloproteinase-1 Enzyme-Linked Immunosorbent Assay

Kaynakça

  • 1. Topuz E, Ayd›ner A. Akci¤er kanseri. In: Topuz E, Ayd›ner A, Karadeniz AN, editors. Klinik onkoloji. ‹stanbul: ‹.Ü. Onkoloji Enstitüsü Yay›nlar›; 2000. p. 82-9.
  • 2. American Joint Commitee on Cancer (AJCC) Cancer staging manual. 5th ed. Philadelphia: LippincortRaven; 1997. p. 127-37.
  • 3. Darendeliler E. Akci¤er kanserinde radyoterapi. In: Topuz E, editör. Akci¤er kanseri. ‹stanbul: ‹.Ü. Onkoloji Enstitüsü Yay›nlar›; 1995. p. 91-102.
  • 4. Ohbayashi H. Matrix metalloproteinases in lung diseases. Curr Protein Pept Sci 2002;3(4):409-21.
  • 5. Springman EB, Angleton EL, Birkedal-Hansen H, Van Wart HE. Multiple modes of activation of latent human fibroblast collagenase: evidence for the role of a Cys73 active-site zinc complex in latency and a "cysteine switch" mechanism for activation. Proc Natl Acad Sci U S A 1990;87(1):364-8.
  • 6. Laack E, Kohler A, Kugler C, Dierlamm T, Knuffmann C, Vohwinkel G, et al. Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann Oncol 2002;13(10):1550-7.
  • 7. Yang SF, Hsieh YS, Lin CL, Hsu NY, Chiou HL, Chou FP, et al. Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients. Clin Chim Acta 2005;354(1-2):91-9.
  • 8. Garbisa S, Scagliotti G, Masiero L, Di Francesco C, Caenazzo C, Onisto M, et al. Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res 1992;52(16):4548-9.
  • 9. Iizasa T, Fujisawa T, Suzuki M, Motohashi S, Yasufuku K, Yasukawa T, et al. Elevated levels of circulating plasma matrix metalloproteinase 9 in nonsmall cell lung cancer patients. Clin Cancer Res 1999;5(1):149-53.
  • 10. Susskind H, Hymowitz MH, Lau YH, Atkins HL, Hurewitz AN, Valentine ES, et al. Increased plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in lung and breast cancer are altered during chest radiotherapy. Int J Radiat Oncol Biol Phys 2003;56(4):1161-9.
  • 11. Pinto CA, Carvalho PE, Antonangelo L, Garippo A, Da Silva AG, Soares F, et al. Morphometric evaluation of tumor matrix metalloproteinase 9 predicts survival after surgical resection of adenocarcinoma of the lung. Clin Cancer Res 2003;9(8):3098-104.
  • 12. Ylisirnio S, Hoyhtya M, Turpeenniemi-Hujanen T. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer- -TIMP-1 as a prognostic marker. Anticancer Res 2000;20(2B):1311-6.
  • 13.Jumper C, Cobos E, Lox C. Determination of the serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in patients with either advanced small-cell lung cancer or non-small-cell lung cancer prior to treatment. Respir Med 2004;98(2):173-7.
  • 14. Leinonen T, Pirinen R, Bohm J, Johansson R, Ropponen K, Kosma VM. Expression of matrix metalloproteinases 7 and 9 in non-small cell lung cancer Relation to clinicopathological factors, beta-catenin and prognosis. Lung Cancer 2006;51(3):313-21.
  • 15. Wang J, Miao LJ, Wu YM, Wu YJ, Wang XC. Expression of AKT2, Cyclin D1, and MMP-9 and Their Correlations to Clinicopathologic Features of Non-small Cell Lung Cancer. [Article in Chinese] Ai Zheng 2006;25(1):69-72. [Abstract]

Matriks metalloproteinazlar ve akciğer kanseri

Yıl 2006, Cilt: 21 Sayı: 2, 53 - 56, 01.03.2006

Hilal Oğuz Soydinç Hakan Çamlıca Derya Duranyıldız Esra Kaytan Sağlam Faruk Taş Vildan Yasasever Nejat Dalay

Öz

AMAÇ Bu çalışmada akciğer kanserli hastalarda matriks metalloproteinaz- 9 (MMP-9) ve doku matriks metalloproteinaz inhibitörü- 1'in (TIMP-1) tedavi öncesi düzeylerinin belirlenmesi amaçlandı. GEREÇ VE YÖNTEM Çalışmamızda cerrahi ve radyoterapi uygulanmamış 20 akciğer kanserli hastada MMP-9 ve TIMP-1 değerleri ELISA yöntemi ile belirlendi ve sağlıklı kontrol grubu ile karşılaştırıldı (n=20). BULGULAR Hastaların MMP-9 (p

Anahtar Kelimeler

Jelatinaz B akciğer kanseri akciğer/metabolizma/radyasyon etkileri akciğer neoplazisi/kan/enzimoloji/radyoterapi Matriks Metalloproteinaz MMP 9 doku matriks metalloproteinaz inhibitörü-1.

Kaynakça

  • 1. Topuz E, Ayd›ner A. Akci¤er kanseri. In: Topuz E, Ayd›ner A, Karadeniz AN, editors. Klinik onkoloji. ‹stanbul: ‹.Ü. Onkoloji Enstitüsü Yay›nlar›; 2000. p. 82-9.
  • 2. American Joint Commitee on Cancer (AJCC) Cancer staging manual. 5th ed. Philadelphia: LippincortRaven; 1997. p. 127-37.
  • 3. Darendeliler E. Akci¤er kanserinde radyoterapi. In: Topuz E, editör. Akci¤er kanseri. ‹stanbul: ‹.Ü. Onkoloji Enstitüsü Yay›nlar›; 1995. p. 91-102.
  • 4. Ohbayashi H. Matrix metalloproteinases in lung diseases. Curr Protein Pept Sci 2002;3(4):409-21.
  • 5. Springman EB, Angleton EL, Birkedal-Hansen H, Van Wart HE. Multiple modes of activation of latent human fibroblast collagenase: evidence for the role of a Cys73 active-site zinc complex in latency and a "cysteine switch" mechanism for activation. Proc Natl Acad Sci U S A 1990;87(1):364-8.
  • 6. Laack E, Kohler A, Kugler C, Dierlamm T, Knuffmann C, Vohwinkel G, et al. Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann Oncol 2002;13(10):1550-7.
  • 7. Yang SF, Hsieh YS, Lin CL, Hsu NY, Chiou HL, Chou FP, et al. Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients. Clin Chim Acta 2005;354(1-2):91-9.
  • 8. Garbisa S, Scagliotti G, Masiero L, Di Francesco C, Caenazzo C, Onisto M, et al. Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res 1992;52(16):4548-9.
  • 9. Iizasa T, Fujisawa T, Suzuki M, Motohashi S, Yasufuku K, Yasukawa T, et al. Elevated levels of circulating plasma matrix metalloproteinase 9 in nonsmall cell lung cancer patients. Clin Cancer Res 1999;5(1):149-53.
  • 10. Susskind H, Hymowitz MH, Lau YH, Atkins HL, Hurewitz AN, Valentine ES, et al. Increased plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in lung and breast cancer are altered during chest radiotherapy. Int J Radiat Oncol Biol Phys 2003;56(4):1161-9.
  • 11. Pinto CA, Carvalho PE, Antonangelo L, Garippo A, Da Silva AG, Soares F, et al. Morphometric evaluation of tumor matrix metalloproteinase 9 predicts survival after surgical resection of adenocarcinoma of the lung. Clin Cancer Res 2003;9(8):3098-104.
  • 12. Ylisirnio S, Hoyhtya M, Turpeenniemi-Hujanen T. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer- -TIMP-1 as a prognostic marker. Anticancer Res 2000;20(2B):1311-6.
  • 13.Jumper C, Cobos E, Lox C. Determination of the serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in patients with either advanced small-cell lung cancer or non-small-cell lung cancer prior to treatment. Respir Med 2004;98(2):173-7.
  • 14. Leinonen T, Pirinen R, Bohm J, Johansson R, Ropponen K, Kosma VM. Expression of matrix metalloproteinases 7 and 9 in non-small cell lung cancer Relation to clinicopathological factors, beta-catenin and prognosis. Lung Cancer 2006;51(3):313-21.
  • 15. Wang J, Miao LJ, Wu YM, Wu YJ, Wang XC. Expression of AKT2, Cyclin D1, and MMP-9 and Their Correlations to Clinicopathologic Features of Non-small Cell Lung Cancer. [Article in Chinese] Ai Zheng 2006;25(1):69-72. [Abstract]
Toplam 15 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Bölüm Makaleler
Yazarlar

Hilal Oğuz Soydinç Bu kişi benim

Hakan Çamlıca Bu kişi benim

Derya Duranyıldız Bu kişi benim

Esra Kaytan Sağlam Bu kişi benim

Faruk Taş Bu kişi benim

Vildan Yasasever Bu kişi benim

Nejat Dalay Bu kişi benim

Yayımlanma Tarihi 1 Mart 2006
Yayımlandığı Sayı Yıl 2006 Cilt: 21 Sayı: 2

Kaynak Göster

APA Soydinç, H. O., Çamlıca, H., Duranyıldız, D., Sağlam, E. K., vd. (2006). Matriks metalloproteinazlar ve akciğer kanseri. Türk Onkoloji Dergisi, 21(2), 53-56.
AMA Soydinç HO, Çamlıca H, Duranyıldız D, Sağlam EK, Taş F, Yasasever V, Dalay N. Matriks metalloproteinazlar ve akciğer kanseri. Türk Onkoloji Dergisi. Mart 2006;21(2):53-56.
Chicago Soydinç, Hilal Oğuz, Hakan Çamlıca, Derya Duranyıldız, Esra Kaytan Sağlam, Faruk Taş, Vildan Yasasever, ve Nejat Dalay. “Matriks Metalloproteinazlar Ve akciğer Kanseri”. Türk Onkoloji Dergisi 21, sy. 2 (Mart 2006): 53-56.
EndNote Soydinç HO, Çamlıca H, Duranyıldız D, Sağlam EK, Taş F, Yasasever V, Dalay N (01 Mart 2006) Matriks metalloproteinazlar ve akciğer kanseri. Türk Onkoloji Dergisi 21 2 53–56.
IEEE H. O. Soydinç, H. Çamlıca, D. Duranyıldız, E. K. Sağlam, F. Taş, V. Yasasever, ve N. Dalay, “Matriks metalloproteinazlar ve akciğer kanseri”, Türk Onkoloji Dergisi, c. 21, sy. 2, ss. 53–56, 2006.
ISNAD Soydinç, Hilal Oğuz vd. “Matriks Metalloproteinazlar Ve akciğer Kanseri”. Türk Onkoloji Dergisi 21/2 (Mart 2006), 53-56.
JAMA Soydinç HO, Çamlıca H, Duranyıldız D, Sağlam EK, Taş F, Yasasever V, Dalay N. Matriks metalloproteinazlar ve akciğer kanseri. Türk Onkoloji Dergisi. 2006;21:53–56.
MLA Soydinç, Hilal Oğuz vd. “Matriks Metalloproteinazlar Ve akciğer Kanseri”. Türk Onkoloji Dergisi, c. 21, sy. 2, 2006, ss. 53-56.
Vancouver Soydinç HO, Çamlıca H, Duranyıldız D, Sağlam EK, Taş F, Yasasever V, Dalay N. Matriks metalloproteinazlar ve akciğer kanseri. Türk Onkoloji Dergisi. 2006;21(2):53-6.